loading
Artelo Biosciences Inc stock is traded at $1.15, with a volume of 1,621. It is up +0.00% in the last 24 hours and down -7.26% over the past month. Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
See More
Previous Close:
$1.15
Open:
$1.15
24h Volume:
1,621
Relative Volume:
0.11
Market Cap:
$3.71M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.3464
EPS:
-3.32
Net Cash Flow:
$-8.96M
1W Performance:
+6.48%
1M Performance:
-7.26%
6M Performance:
-24.59%
1Y Performance:
-6.50%
1-Day Range:
Value
$1.15
$1.17
1-Week Range:
Value
$1.02
$1.32
52-Week Range:
Value
$1.00
$1.75

Artelo Biosciences Inc Stock (ARTL) Company Profile

Name
Name
Artelo Biosciences Inc
Name
Phone
858-925-7049
Name
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Name
Employee
6
Name
Twitter
@ArteloBio
Name
Next Earnings Date
2024-12-11
Name
Latest SEC Filings
Name
ARTL's Discussions on Twitter

Compare ARTL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ARTL 1.17 3.71M 0 -9.60M -8.96M -3.32
VRTX 449.15 115.74B 10.63B -479.80M -1.35B 13.33
REGN 744.75 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.91 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.52 24.49B 3.30B -501.07M 1.03B 11.54

Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-12-21 Initiated Ladenburg Thalmann Buy

Artelo Biosciences Inc Stock (ARTL) Latest News

pulisher
Nov 20, 2024

Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com

Nov 20, 2024
pulisher
Nov 18, 2024

Artelo Biosciences to Present Key Drug Development Data at Major Cannabinoid Summit | ARTL Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings - Defense World

Nov 18, 2024
pulisher
Nov 15, 2024

HC Wainwright Reiterates “Buy” Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Cancer Anorexia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals - The Globe and Mail

Nov 14, 2024
pulisher
Nov 13, 2024

Artelo Biosciences Reports Q3 2024 Financials and Progress - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Artelo Biosciences (ARTL) Stock Dips Amidst Financial Report - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Artelo's Pain Drug Outperforms Naproxen in Key Study; FDA Clears Phase 1 Trial | ARTL Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Artelo Bio Slashes Losses 54%, Advances Pipeline with Multiple Clinical Trials Ahead | ARTL Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

Artelo Biosciences (ARTL) Shares Dive Amidst Biotech Sector Move - GuruFocus.com

Nov 07, 2024
pulisher
Nov 05, 2024

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program - StockTitan

Nov 05, 2024
pulisher
Oct 16, 2024

Artelo Biosciences (ARTL) Stock Surges Amid Bullish Analyst Rati - GuruFocus.com

Oct 16, 2024
pulisher
Oct 09, 2024

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th - The Manila Times

Oct 09, 2024
pulisher
Oct 05, 2024

How doctors hope new cannabis drug will help cancer patients gain weight - inews

Oct 05, 2024
pulisher
Oct 02, 2024

FABP5 inhibitor ART-26.12 exhibits activity in psoriasis models - BioWorld Online

Oct 02, 2024
pulisher
Oct 01, 2024

Artelo Biosciences shares initiated with Buy by EF Hutton - Investing.com UK

Oct 01, 2024
pulisher
Oct 01, 2024

EF Hutton Initiates Coverage of Artelo Biosciences (ARTL) with Buy Recommendation - MSN

Oct 01, 2024
pulisher
Sep 27, 2024

Equities Analysts Offer Predictions for Stitch Fix, Inc.’s Q1 2025 Earnings (NASDAQ:SFIX) - Defense World

Sep 27, 2024
pulisher
Sep 27, 2024

Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World

Sep 27, 2024
pulisher
Sep 19, 2024

Anorexia Nervosa Market Expected to Experience Major Growth - openPR

Sep 19, 2024
pulisher
Sep 10, 2024

ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com Canada

Sep 10, 2024
pulisher
Sep 04, 2024

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com

Sep 04, 2024
pulisher
Aug 21, 2024

ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 - MSN

Aug 21, 2024
pulisher
Aug 18, 2024

ARTLW (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 18, 2024

ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 17, 2024

ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

HC Wainwright Weighs in on Artelo Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:ARTL) - Defense World

Aug 17, 2024
pulisher
Aug 15, 2024

Artelo Biosciences’ (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Artelo Biosciences (NASDAQ:ARTL) Announces Earnings Results - Defense World

Aug 15, 2024
pulisher
Aug 13, 2024

Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace

Aug 13, 2024
pulisher
Aug 13, 2024

Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 3,808.3% in July - Defense World

Aug 13, 2024
pulisher
Jul 26, 2024

Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 91.5% in July - Defense World

Jul 26, 2024
pulisher
Jul 20, 2024

New drug to control pain related to cancer treatment originally developed at Stony Brook gets FDA clearance - TBR News Media

Jul 20, 2024
pulisher
Jul 19, 2024

UK life sciences can lead the way in global cannabinoid R&D says CRDG report - European Pharmaceutical Manufacturer

Jul 19, 2024
pulisher
Jul 16, 2024

Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy - BioWorld Online

Jul 16, 2024
pulisher
Jul 16, 2024

Artelo Biosciences Inc (ARTL)’s Market Momentum: Closing Strong at 1.33, Up 2.71 - The Dwinnex

Jul 16, 2024
pulisher
Jul 15, 2024

FDA greenlights Artelo Biosciences' neuropathy drug trial By Investing.com - Investing.com Nigeria

Jul 15, 2024
pulisher
Jul 15, 2024

PSEG sets $0.60 quarterly dividend for Q3 2024 By Investing.com - Investing.com

Jul 15, 2024
pulisher
Jul 15, 2024

Artelo Biosciences Inc (ARTL) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Jul 15, 2024
pulisher
Jul 15, 2024

FDA clears Artelo’s FABP5 inhibitor trial - Yahoo Finance

Jul 15, 2024
pulisher
Jul 15, 2024

Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study (NASDAQ:ARTL) - Seeking Alpha

Jul 15, 2024
pulisher
Jul 15, 2024

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor - ForexTV.com

Jul 15, 2024
pulisher
Jul 05, 2024

Pharmacokinetic evaluation of novel cannabidiol formulation presented - BioWorld Online

Jul 05, 2024
pulisher
Jul 03, 2024

Artelo Biosciences Presents Data From Preclinical Studies On ART12.11 At 34th Annual International Cannabinoid Research Society Symposium - Quantisnow

Jul 03, 2024
pulisher
Jul 03, 2024

Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium - Yahoo Finance

Jul 03, 2024
pulisher
Jul 02, 2024

Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform - StockTitan

Jul 02, 2024
pulisher
Jul 01, 2024

Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium - Quantisnow

Jul 01, 2024
pulisher
Jun 29, 2024

Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90 ... - The Globe and Mail

Jun 29, 2024

Artelo Biosciences Inc Stock (ARTL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):